Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
64.53(c) 65.01(c) 63.5(c) 62.98(c) 64.43(c) Last
5 615 704 7 215 089 9 373 304 9 195 726 8 044 003 Volume
-1.60% +0.74% -2.32% -0.82% +2.30% Change
More quotes
Financials (USD)
Sales 2019 33 077 M
EBIT 2019 15 682 M
Net income 2019 9 260 M
Debt 2019 29 942 M
Yield 2019 6,65%
Sales 2020 34 718 M
EBIT 2020 16 324 M
Net income 2020 10 978 M
Debt 2020 26 181 M
Yield 2020 7,17%
P/E ratio 2019 10,1x
P/E ratio 2020 7,84x
EV / Sales2019 3,79x
EV / Sales2020 3,50x
Capitalization 95 259 M
More Financials
Company
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with... 
Sector
Pharmaceuticals
Calendar
10/26 | 11:00pmEarnings Release
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
08/16Health Care Up as Risk Appetite Buoys Biotech -- Health Care Roundup
DJ
08/16ABBVIE : Gets FDA OK for Rheumatoid Arthritis Drug Rinvoq
DJ
08/16ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/14ABBVIE : Form 8.3 - Allergan Plc
DJ
08/14ALEMBIC : Pharmaceuticals receives USFDA Approval for Fenofibrate Tablets USP, 4..
AQ
08/13ALLERGAN : Form 8.3 -Allergan Plc
DJ
08/09ABBVIE : Form 8.3 -
DJ
08/08ABBVIE : Form 8.3 -Allergan Plc
DJ
08/08ABBVIE : Form 8.3 -AbbVie Inc
AQ
08/06ABBVIE : Form 8.3 -
AQ
More news
Analyst Recommendations on ABBVIE
More recommendations
Sector news : Pharmaceuticals - NEC
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/16NOVO NORDISK : contests Danish lawsuit claiming $1.75 billion
RE
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
DJ
08/15GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
More sector news : Pharmaceuticals - NEC
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 85,58  $
Last Close Price 64,43  $
Spread / Highest target 78,5%
Spread / Average Target 32,8%
Spread / Lowest Target 7,09%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Senior Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-30.11%93 115
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.10.66%235 575
ROCHE HOLDING12.11%235 575
MERCK AND COMPANY9.23%213 689
NOVARTIS17.91%202 958